In addition, compared with the low RAC3 expression, the high RAC3 expression was linked to poorer outcomes in individuals with bladder cancer, KIRC, sarcoma, and thyroid carcinoma, but longer survival in breast cancer and PDAC (Figure S4C). Here, RAC3 is linked to sarcoma.